Edgewise Therapeutics, Inc.

NasdaqGS:EWTX Voorraadrapport

Marktkapitalisatie: US$4.3b

Edgewise Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

Edgewise Therapeutics zal naar verwachting groeien in winst en omzet met respectievelijk 20.7% en 37.9% per jaar. De winst per aandeel zal naar verwachting groeien met 20% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -7.6% zijn.

Belangrijke informatie

20.7%

Groei van de winst

20.03%

Groei van de winst per aandeel

Pharmaceuticals winstgroei15.1%
Inkomstengroei37.9%
Toekomstig rendement op eigen vermogen-7.58%
Dekking van analisten

Good

Laatst bijgewerkt17 Jul 2026

Recente toekomstige groei-updates

Recent updates

Seeking Alpha • Jun 05

Edgewise: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 Advancement

Summary Edgewise Therapeutics remains a "Buy," driven by pipeline focus and a transformative $2.65B sale of its muscular dystrophy program to Servier. Company will use the $1.55B upfront cash to fully fund EDG-7500 development for oHCM/nHCM, targeting pivotal phase 3 initiation in Q4 2026. Topline 12-week Part D data from the phase 2 CIRRUS-HCM study for EDG-7500 is expected in Q2 2026, a key catalyst for advancing to phase 3. A robust cash position extends the runway to a potential EDG-7500 approval, while EWTX pivots entirely to its cardiovascular pipeline and advances EDG-15400 for HFpEF. Read the full article on Seeking Alpha
Analyse-artikel • Mar 12

Here's Why We're Not At All Concerned With Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Mar 10

Edgewise Therapeutics: More Expensive Now, But Much More Derisked

Summary Edgewise Therapeutics' stock surged after strong midstage data from its Becker Muscular Dystrophy program, with the lead molecule sevasemten showing promising results. The GRAND CANYON trial, targeting Becker Muscular Dystrophy, aims for regulatory approval with primary endpoint NSAA, following positive Phase 2 CANYON data. Financially, Edgewise has a market cap of $2.67bn and a cash runway of 8-9 quarters, supporting ongoing and future trials. Despite the increased stock price, EWTX remains a buy due to its derisked status and potential success across multiple myosin inhibition programs. Read the full article on Seeking Alpha
Seeking Alpha • Dec 31

Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data

Summary Company achieved positive phase 2 CANYON study results for sevasemten in Becker Muscular Dystrophy, boosting long-term investment potential. Key catalysts include FDA and EMA meetings, GRAND CANYON study recruitment completion, and phase 2 CANYON data publication, all expected to likely enhance shareholder value. The pipeline extends beyond BMD, with sevasemten in phase 2 trials for Duchenne Muscular Dystrophy and EDG-7500 targeting Hypertrophic Cardiomyopathy, offering multiple growth opportunities. The global Becker Muscular Dystrophy market is expected to reach $1.28 billion by 2034. Read the full article on Seeking Alpha
Analyse-artikel • Nov 26

Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. By way of example, Edgewise...
Seeking Alpha • Sep 19

Edgewise: Stock Is Bouncing On Heart Disease Drug Data, Albeit From Just 7 Patients (Rating Upgrade)

Summary I previously rated Edgewise Therapeutics a sell due to limited market potential and lack of clinical data for sevasemten. Sevasemten, Edgewise's lead drug, remains unchanged in its potential, with ongoing pivotal studies for Becker Muscular Dystrophy. Edgewise stock has surged over 50% today however on Phase 1 data for EDG-7500, a cardiac sarcomere modulator for hypertrophic cardiomyopathy and diastolic dysfunction. The positive Phase 1 data for EDG-7500 significantly impacts Edgewise's valuation, highlighting the importance of considering early-stage assets. There is a long path to a potential approval shot, however, and the reliability of a 7-patient data set is not sufficient for a "buy" recommendation at this time. One for the watchlist. Read the full article on Seeking Alpha
Analyse-artikel • Aug 12

We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Edgewise...
Seeking Alpha • Aug 05

Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal

Summary Edgewise Therapeutics develops small molecules for myopathies, with lead molecule sevasemten in phase 3 for Becker Muscular Dystrophy. Company was founded in 2017, backed by OrbiMed, with an experienced management team and strong financials. Sevasemten offers a genotype-agnostic approach, competitive difference from dystrophin-targeting therapies, with potential high market valuation. Read the full article on Seeking Alpha
Seeking Alpha • May 10

Edgewise: Intriguing Drug Candidate, But Consider Selling After Recent Run

Summary Edgewise Therapeutics, Inc. reported its first quarter earnings, revealing a strong cash position of $532m and a net loss of $(28.5m). The company is advancing two clinical-stage programs, including a pivotal trial for Becker muscular dystrophy and a Phase 1 trial for hypertrophic cardiomyopathy for a second candidate. Sevasemten, the lead drug candidate, showed positive results in a two-year study for Becker muscular dystrophy, supporting the hypothesis that it can preserve and improve muscle function. An FDA Fast Track designation for sevasemten has triggered a bull run that has seen the share price gain by >250%. A lack of genuinely meaningful catalysts in 2024, and a lengthy wait until an application for approval can be made, make this a good time to sell, in my view, although long-term, there are signs the drug is approvable. Read the full article on Seeking Alpha
Analyse-artikel • May 10

We're Not Very Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, Edgewise Therapeutics...
Seeking Alpha • Feb 18

Edgewise Therapeutics: Behind The Massive Rally

Summary Edgewise Therapeutics' stock has rallied massively after receiving FDA designations for its lead asset, EDG-5506, which has a potential $750 million opportunity in BMD. The company is focused on developing precision medicines for severe genetic neuromuscular and cardiac disorders. Edgewise Therapeutics has recently raised additional capital and has four data readouts for EDG-5506 scheduled for 2024. A full investment analysis around Edgewise Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Analyse-artikel • Dec 07

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analyse-artikel • Aug 16

Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyse-artikel • Apr 28

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analyse-artikel • Jan 13

We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Sep 13

Edgewise Therapeutics proposes $100M stock offering plan

Edgewise Therapeutics (NASDAQ:EWTX) announced Tuesday its plans to raise $100M in the underwritten public stock offering; price, size and other terms not yet determined. The Colorado-based biopharmaceutical company told underwriters will be granted an overallotment option to purchase up to an additional $15M shares. It comes right after Edgewise Therapeutics received FDA's approval for phase 2 trial of its experimental drug, EDG-5506, in children with muscular dystrophy. Stock is down 2% in pre-market trading.

Winst- en omzetgroeiprognoses

NasdaqGS:EWTX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/202855-197N/A-1687
12/31/202753-175-68-748
12/31/2026209-209-4432018
3/31/2026N/A-176-149-148N/A
12/31/2025N/A-168-144-144N/A
9/30/2025N/A-157-133-132N/A
6/30/2025N/A-151-126-125N/A
3/31/2025N/A-146-119-118N/A
12/31/2024N/A-134-110-109N/A
9/30/2024N/A-124-110-109N/A
6/30/2024N/A-116-105-104N/A
3/31/2024N/A-106-99-98N/A
12/31/2023N/A-100-98-92N/A
9/30/2023N/A-89-86-77N/A
6/30/2023N/A-81-77-67N/A
3/31/2023N/A-76-72-63N/A
12/31/2022N/A-68-58-53N/A
9/30/2022N/A-61-53-50N/A
6/30/2022N/A-56-48-46N/A
3/31/2022N/A-51-41-40N/A
12/31/2021N/A-43-34-34N/A
9/30/2021N/A-36-29-29N/A
6/30/2021N/A-27-24-24N/A
3/31/2021N/A-21-18-18N/A
12/31/2020N/A-17-15-15N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat EWTX de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat EWTX de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat EWTX de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van EWTX ( 37.9% per jaar) zal naar verwachting sneller groeien dan de markt US ( 12.8% per jaar).

Hoge groei-inkomsten: De omzet van EWTX ( 37.9% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat EWTX binnen 3 jaar verliesgevend zal zijn.

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/07/22 13:27
Aandelenkoers aan het einde van de dag2026/07/22 00:00
Inkomsten2026/03/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Edgewise Therapeutics, Inc. wordt gevolgd door 15 analisten. 8 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Cory KasimovEvercore ISI
Paul ChoiGoldman Sachs
Debjit ChattopadhyayGuggenheim Securities, LLC